ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights for the third quarter ended September 30, 2025, before the market opens on Thursday, November 6, 2025. About Quoin Pharmaceuticals Ltd.Quoin P ...

Financial Performance - Q3 2025 revenue reached $785 million, a 12% increase compared to Q3 2024[5] - Adjusted EBITDA for Q3 2025 was $160 million, a 1% increase year-over-year[5] - Adjusted EPS for Q3 2025 was $017, a 6% increase compared to Q3 2024[5] - The company updates 2025 guidance for adjusted EBITDA between $675 million to $685 million and adjusted EPS of $075 to $080[5] Segment Performance - AvKARE segment experienced substantial revenue growth of 24% in Q3[5] - Specialty segment grew 8% in Q3, driven by CREXONT® and UNITHROID®[5] - Affordable Medicines segment grew 8% in Q3, driven by complex products and new launches[5] Product and Pipeline - CREXONT® uptake continues with approximately 17000 Parkinson's patients on therapy[5] - Brekiya® DHE autoinjector launched for migraine & cluster headache[5] - Biosimilars portfolio poised to expand, including BLA submission for bXOLAIR® in September[5]

Novo Nordisk A/S made an unsolicited bid for US biotech firm Metsera Inc., sparking a heated battle with Pfizer Inc. to get their hands on weight-loss treatments that both drugmakers want in order to regain lost ground in the booming market. Novo offered to buy Metsera Inc. for at least $6.5 billion, seeking to trump an earlier agreed deal with Pfizer. Metsera called the new offer, which Bloomberg News reported earlier on Thursday, superior to the previous one from Pfizer that it had accepted last month. ...

Eli Lilly's stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook. ...

(Reuters) -Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong appetite for its widely popular weight-loss and diabetes drugs Zepbound and Mounjaro helped it breeze past third-quarter earnings estimates. Shares of the world's largest healthcare firm by market capitalization jumped over 5% in premarket trading even as investors remain wary of drug price negotiations with the Trump administration. Lilly competes with Novo Nordisk for the top spot in the weight-loss drug market ...

BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its third quarter financial results after the close of the U.S. markets on Thursday November 6, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and ans ...

Third-Quarter 2025 Earnings Presentation October 30, 2025 1 Forward Looking Statements The forward-looking statements in this presentation are based upon the Company's current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or indicated in any fo ...

SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present poster presentations at ObesityWeek® 2025, taking place November 4-7, 2025 in Atlanta, Georgia. The presentations will highlight preclinical data for BMF-650, Biomea’s next-generation oral small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), and combination data for icovamenib, the company’s fir ...

THIRD QUARTER 2025 EARNINGS CONFERENCE CALL Question & Answer Steven Basta, President & Chief Executive Officer Sanjeev Narula, Chief Financial and Business Officer Robert Breedlove, Principal Accounting Officer OCTOBER 2025 NASDAQ: PHAT Today's Agenda Business Update Steven Basta, President & Chief Executive Officer Q3 2025 Financial Results Sanjeev Narula, Chief Financial and Business Officer Closing Remarks Steven Basta, President & Chief Executive Officer 2 Safe harbor This presentation contains forward ...

BASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. To join the ...